Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046248 · ClinicalTrials.gov registry record · Phase 2
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06046248: Recruiting Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Northside Hospital.
NCT06046248 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 25 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046248, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Belumosudil
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06046248 shows while recruiting
NCT06046248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT06046248 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06046248 about?
NCT06046248 is a clinical study titled "Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease". This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
What is the current status of trial NCT06046248?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-01-29. Estimated completion is 2027-12-31.
What conditions does trial NCT06046248 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT06046248?
The interventions under investigation include: Rituximab (DRUG), Belumosudil (DRUG).
Who is sponsoring clinical trial NCT06046248?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046248 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06046248's enrollment target sits among peer trials
25 21st of 30 higher than 9 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
RECRUITING · Phase 2
-
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI